Greater PSA Decline Predicts Better 177Lu-PSMA-617 Outcomes in mCRPC
Latest findings are from a post hoc analysis of the phase 3 VISION trial.
Radiotherapy
Study: 177Lutetium-PSMA-617 After 223Radium for mCRPC Safe, Effective
Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…
Upstaging After PSMA PET for High-Risk Prostate Cancer Increasing
Study findings suggest that PSMA PET results may alter treatment decisions in high-risk prostate cancer.
Local Failure After Prostate Cancer RT Linked to Distant Metastases
Distant metastases in patients who experience local treatment failure after receiving radiotherapy for intermediate- and high-risk prostate cancer often occurs without prior detectable local recurrence, a meta-analysis shows.
Rural Residence Tied to Poorer Adherence to RT for Cancer
Also, two-year survival only 27% for rural cancer patients who experience a treatment delay
Prostate Cancer Radiation Therapy Ups Risks for a Second Cancer
Although the risks of developing a second primary cancer after radiation therapy were relatively small, they increased over time.
Adjuvant Radiation Tx May Benefit Select Men With High-Risk Prostate Cancer
A novel scoring system could identify men at increased risk of death after prostatectomy who would benefit from adjuvant radiation therapy.
Data Support Trimodal Therapy for Muscle-Invasive Bladder Cancer
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Second Primary Cancers Less Likely With IMRT vs CRT for Prostate Tumors
Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.
Recent Cancer Treatment Linked to Worse COVID-19 Outcomes
However, a history of cancer more than one year before COVID-19 diagnosis not tied to increased mortality or hospitalization
- Loading...
Loading...
Next post in News
Loading... 
Loading...